"Our partnership with PARI has given us access
to
their eFlow® electronic nebulizer, their
expertise in drug formulations and the complex
interaction between the two. The eFlow performed
well in the Corus
Phase 2 clinical trials and is being utilized in
our
Phase 3 program. We are excited about the
potential
of bringing our product to market which will be
the
first commercially available product for use
specifically with the eFlow."
Bruce Montgomery, MD
Gilead Sciences
We can take on various roles in our pharmaceutical partner relationships
Often we develop a comprehensive aerosol therapy
development program that includes all formulation
development, formulation and device
optimization, development of analytical methods
and aerosol testing, and regulatory support.
However, if our pharma partner is in advanced
development with a given formulation, we can
focus our efforts on
optimization of the Advanced Aerosol Delivery platform
(such as eFlow) and optimize the formulation to
the device. Mutual Business Development
conditions are dictated by each partner’s
contributions to the project.
[enlarge
view]
|
